L. Reunes

Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.

C. Mecucci, J. Barata, N. Van Roy, 2020, Blood.

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.

M. Loh, S. van Calenbergh, C. Mullighan, 2021, The Journal of clinical investigation.

Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies

G. Berx, J. Haigh, P. Van Vlierberghe, 2019, Scientific Reports.

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and

W. Klapper, B. Burkhardt, E. Macintyre, 2018 .

Genetic characterization and therapeutic targeting of MYC‐rearranged T cell acute lymphoblastic leukaemia

M. Loh, S. Raimondi, G. Berx, 2018, British journal of haematology.

In vivo stabilization of a less toxic asparaginase variant leads to a durable antitumor response in acute leukemia

A. Lavie, P. Van Vlierberghe, P. Lorenzi, 2022, Haematologica.

Cell-penetrating Alphabody protein scaffolds for intracellular drug targeting

I. Lasters, J. Desmet, S. Savvides, 2021, Science Advances.